• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：SNORA72激活Notch1/c-Myc信号通路以促进卵巢癌细胞的干性转化。

Corrigendum: SNORA72 activates the Notch1/c-Myc pathway to promote stemness transformation of ovarian cancer cells.

作者信息

Zhang Liwen, Ma Rong, Gao Mengcong, Zhao Yanyun, Lv Xuemei, Zhu Wenjing, Han Li, Su Panpan, Fan Yue, Yan Yuanyuan, Zhao Lin, Ma Heyao, Wei Minjie, He Miao

机构信息

Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.

Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China.

出版信息

Front Cell Dev Biol. 2022 Aug 26;10:819798. doi: 10.3389/fcell.2022.819798. eCollection 2022.

DOI:10.3389/fcell.2022.819798
PMID:36092736
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9462444/
Abstract

[This corrects the article DOI: 10.3389/fcell.2020.583087.].

摘要

[本文更正了文章DOI：10.3389/fcell.2020.583087。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc36/9462444/a11b2ff02390/fcell-10-819798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc36/9462444/a11b2ff02390/fcell-10-819798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc36/9462444/a11b2ff02390/fcell-10-819798-g001.jpg

相似文献

1
Corrigendum: SNORA72 activates the Notch1/c-Myc pathway to promote stemness transformation of ovarian cancer cells.勘误：SNORA72激活Notch1/c-Myc信号通路以促进卵巢癌细胞的干性转化。
Front Cell Dev Biol. 2022 Aug 26;10:819798. doi: 10.3389/fcell.2022.819798. eCollection 2022.
2
SNORA72 Activates the Notch1/c-Myc Pathway to Promote Stemness Transformation of Ovarian Cancer Cells.SNORA72激活Notch1/c-Myc信号通路以促进卵巢癌细胞的干性转化。
Front Cell Dev Biol. 2020 Nov 3;8:583087. doi: 10.3389/fcell.2020.583087. eCollection 2020.
3
SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway.SNORD89 通过调控 Notch1-c-Myc 通路促进卵巢癌细胞干性表型。
J Transl Med. 2019 Aug 8;17(1):259. doi: 10.1186/s12967-019-2005-1.
4
γ-Secretase Inhibitor, DAPT Inhibits Self-renewal and Stemness Maintenance of Ovarian Cancer Stem-like Cells In Vitro.γ-分泌酶抑制剂 DAPT 抑制卵巢癌干细胞样细胞的自我更新和干性维持。
Chin J Cancer Res. 2011 Jun;23(2):140-6. doi: 10.1007/s11670-011-0140-1.
5
HOTAIR maintains the stemness of ovarian cancer stem cells via the miR-206/TBX3 axis.HOTAIR 通过 miR-206/TBX3 轴维持卵巢癌细胞干细胞的干性。
Exp Cell Res. 2020 Oct 15;395(2):112218. doi: 10.1016/j.yexcr.2020.112218. Epub 2020 Aug 6.
6
Corrigendum: A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth.勘误：Notch1的小分子抑制剂调节干性并抑制乳腺癌细胞生长。
Front Pharmacol. 2023 May 3;14:1207589. doi: 10.3389/fphar.2023.1207589. eCollection 2023.
7
Corrigendum: A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth.勘误：Notch1小分子抑制剂调节干性并抑制乳腺癌细胞生长。
Front Pharmacol. 2024 May 27;15:1420266. doi: 10.3389/fphar.2024.1420266. eCollection 2024.
8
Corrigendum: An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness.勘误：FGFR/AKT/SOX2信号轴控制胰腺癌干性。
Front Cell Dev Biol. 2020 Oct 2;8:594589. doi: 10.3389/fcell.2020.594589. eCollection 2020.
9
miR-449c-5p availability is antagonized by circ-NOTCH1 for MYC-induced NOTCH1 upregulation as well as tumor metastasis and stemness in gastric cancer.miR-449c-5p 的可用性受到 circ-NOTCH1 的拮抗作用，circ-NOTCH1 可上调 MYC 诱导的 NOTCH1，促进胃癌的转移和干性。
J Cell Biochem. 2020 Oct;121(10):4052-4063. doi: 10.1002/jcb.29575. Epub 2020 Jan 14.
10
LINC00115 promotes stemness and inhibits apoptosis of ovarian cancer stem cells by upregulating SOX9 and inhibiting the Wnt/β-catenin pathway through competitively binding to microRNA-30a.LINC00115通过上调SOX9并通过竞争性结合微小RNA-30a抑制Wnt/β-连环蛋白通路，促进卵巢癌干细胞的干性并抑制其凋亡。
Cancer Cell Int. 2021 Jul 8;21(1):360. doi: 10.1186/s12935-021-02019-2.